Introducing a Single IV Abatacept Treatment in RA Patients Currently Receiving Weekly SC Abatacept to Simulate a Holiday
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
RA (rheumatoid arthritis) patients effectively treated weekly with SC (subcutaneous)
Abatacept will be switched to IV (intravenous) Abatacept and restarted with SC Abatacept four
after IV application. The investigators hypothesize that a switch from SC- to IV-abatacept
and back in patients with low disease activity is safe and not associated with a worsening of
the disease.